Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study

Documenti analoghi

• Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
  di: Tomasini, Pascale, et al.
  Pubblicazione: (2018)
• Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
  di: Hida, Toyoaki, et al.
  Pubblicazione: (2020)
• Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
  di: Gray, Jhanelle E., et al.
  Pubblicazione: (2019)
• Long‐term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non‐small‐cell lung cancer
  di: Horinouchi, Hidehito, et al.
  Pubblicazione: (2012)
• Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer
  di: Chiramel, Jaseela, et al.
  Pubblicazione: (2018)